BACKGROUND: Previous studies have reported an association between anti-psychotic medications and diabetes. OBJECTIVE: To explore the association between antipsychotic medications and diabetes in patients of different ages. METHODS: A retrospective analysis of a large health maintenance organization's drug claim database (3.7 million members) was performed. All patients treated with antipsychotic drugs during 1998-2004 were identified. Patients with diabetes were defined by a record of antidiabetic drug use during 2004. The prevalence of diabetes in different age groups treated with antipsychotics was compared with the prevalence of diabetes among enrollees in the same age groups not treated with antipsychotics. RESULTS: Among 82,754 patients treated with antipsychotics, the association between diabetes and consumption of antipsychotics was strongest in the younger age groups and decreased with increasing age: for patients aged 0-24 years, OR 8.9 (95% CI 7.0 to 11.3); 25-44 years, OR 4.2 (95% CI 3.8 to 4.5); 45-54 years, OR 1.9 (95% CI 1.8 to 2.1); 55-64 years, OR 1.3 (95% CI 1.2 to 1.4); and 65 years or older, OR 0.93 (95% CI 0.9 to 1.0). However, the risk associated with atypical antipsychotics was lower than the risk associated with typical antipsychotics, with ORs ranging from 0.7 in patients 0-24 years old to 0.3 in those 65 years or older. CONCLUSIONS: Antipsychotic drug use was associated with diabetes mellitus. This association was stronger in younger patients. In older adults, the difference was much smaller and, in some cases, there was no association. A lower risk was associated with atypical agents, as compared with typical antipsychotics. Clinicians should be aware that young adults treated with antipsychotics are at increased risk for diabetes.
BACKGROUND: Previous studies have reported an association between anti-psychotic medications and diabetes. OBJECTIVE: To explore the association between antipsychotic medications and diabetes in patients of different ages. METHODS: A retrospective analysis of a large health maintenance organization's drug claim database (3.7 million members) was performed. All patients treated with antipsychotic drugs during 1998-2004 were identified. Patients with diabetes were defined by a record of antidiabetic drug use during 2004. The prevalence of diabetes in different age groups treated with antipsychotics was compared with the prevalence of diabetes among enrollees in the same age groups not treated with antipsychotics. RESULTS: Among 82,754 patients treated with antipsychotics, the association between diabetes and consumption of antipsychotics was strongest in the younger age groups and decreased with increasing age: for patients aged 0-24 years, OR 8.9 (95% CI 7.0 to 11.3); 25-44 years, OR 4.2 (95% CI 3.8 to 4.5); 45-54 years, OR 1.9 (95% CI 1.8 to 2.1); 55-64 years, OR 1.3 (95% CI 1.2 to 1.4); and 65 years or older, OR 0.93 (95% CI 0.9 to 1.0). However, the risk associated with atypical antipsychotics was lower than the risk associated with typical antipsychotics, with ORs ranging from 0.7 in patients 0-24 years old to 0.3 in those 65 years or older. CONCLUSIONS: Antipsychotic drug use was associated with diabetes mellitus. This association was stronger in younger patients. In older adults, the difference was much smaller and, in some cases, there was no association. A lower risk was associated with atypical agents, as compared with typical antipsychotics. Clinicians should be aware that young adults treated with antipsychotics are at increased risk for diabetes.
Authors: Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll Journal: Nat Rev Endocrinol Date: 2011-10-18 Impact factor: 43.330
Authors: Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom Journal: J Child Adolesc Psychopharmacol Date: 2014-08-21 Impact factor: 2.576
Authors: Almut G Winterstein; Paul Kubilis; Steve Bird; Rhonda M Cooper-DeHoff; Greg A Nichols; Joseph A Delaney Journal: Pharmacoepidemiol Drug Saf Date: 2014-06-12 Impact factor: 2.890
Authors: Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll Journal: World Psychiatry Date: 2015-10 Impact factor: 49.548
Authors: Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548